Abstract
Objective: To evaluate the efficacy of pharmaceutical care in improving outcomes of Brazilian outpatients with type 2 diabetes mellitus. Methods: In this single-blind, controlled trial, 71 outpatients were randomized into two groups: pharmaceutical care intervention (managed using pharmacotherapy follow-up protocol); and control (managed using standard dispensing procedures). Outcomes included hospitalization, severe complication (retinopathy, renal insufficiency, hypoglycemia, coronaropathy or foot lesion), and the values of A1c hemoglobin (HbA1c), capillary glycaemia (CG), blood pressure (BP), total cholesterol (TC) and body mass index (BMI). All patients were followed for 12 months and drug-related problems (DRP) were described in intervention group. The groups were compared using the Student´s t-test, Tukey-Kramer, Chi-square and Fisher exact tests. Results: No significant difference in baseline clinical characteristics of the intervention (n= 36) and control groups (n= 35) (p>0.05). The groups did not differ for the outcome hypoglycemia, CG, BP, HbA1c, TC and BMI (p>0.05), but CG and HbA1c levels decreased at 3, 6 and 12 months, in both groups (p≤0.05). A total of 56 DRP were observed in intervention group and the pharmacist resolved approximately 60% of these. Conclusion: Improvements in the glycemic parameters of outpatients with type 2 diabetes mellitus attended within a community pharmacy were observed. Studies involving larger samples are needed to confirm the benefits of pharmacotherapy follow-up care for key clinical outcomes in these patients. The trial was registered in Clinicaltrials.gov: Record NCT03196336.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.